An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kronos Bio will present a clinical update on the Phase 1/2 trial of KB-0742 at the 2024 ASCO Annual Meeting. The study update will focus on the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors. The trial aims to assess safety, tolerability, and preliminary efficacy of KB-0742 at increasing dose levels. The presentation will be led by Brian A. Van Tine, M.D., Ph.D., from Washington University in St. Louis.
Kronos Bio presenterà un aggiornamento clinico sullo studio di Fase 1/2 di KB-0742 durante l'incontro annuale dell'ASCO del 2024. L'aggiornamento dello studio si concentrerà sull'inibitore orale CDK9 KB-0742 in tumori solidi avanzati recidivi o refrattari alla trascrizione. L'obiettivo della sperimentazione è valutare la sicurezza, la tollerabilità e l'efficacia preliminare di KB-0742 a dosi crescenti. La presentazione sarà guidata da Brian A. Van Tine, M.D., Ph.D., della Washington University di St. Louis.
Kronos Bio presentará una actualización clínica del ensayo de Fase 1/2 de KB-0742 en la Reunión Anual de la ASCO de 2024. La actualización del estudio se centrará en el inhibidor oral CDK9 KB-0742 en tumores sólidos avanzados recaídos o refractarios adictos a la transcripción. El ensayo tiene como objetivo evaluar la seguridad, la tolerabilidad y la eficacia preliminar de KB-0742 en niveles de dosis crecientes. La presentación será dirigida por Brian A. Van Tine, M.D., Ph.D., de la Universidad de Washington en St. Louis.
크로노스 바이오는 2024년 ASCO 연례 회의에서 KB-0742의 1/2단계 임상시험 업데이트를 발표할 것입니다. 이 연구 업데이트는 재발하거나 내성을 보이는 전사 중독성 진행성 고형암에 대한 경구용 CDK9 억제제 KB-0742에 초점을 맞출 것입니다. 이 시험은 KB-0742의 안전성, 내약성 및 초기 효능을 증가하는 용량 수준에서 평가하려고 합니다. 발표는 워싱턴 대학교 세인트루이스의 Brian A. Van Tine, M.D., Ph.D.가 이끌게 됩니다.
Kronos Bio présentera une mise à jour clinique sur l'essai de phase 1/2 de KB-0742 lors de la réunion annuelle de l'ASCO en 2024. La mise à jour de l'étude se concentrera sur l'inhibiteur oral CDK9 KB-0742 pour les tumeurs solides avancées récidivantes ou réfractaires à transcription. L'objectif de l'essai est d'évaluer la sécurité, la tolérabilité et l'efficacité préliminaire de KB-0742 à des niveaux de dose croissants. La présentation sera dirigée par Brian A. Van Tine, M.D., Ph.D., de l'Université de Washington à St. Louis.
Kronos Bio wird ein klinisches Update zur Phase 1/2-Studie von KB-0742 auf der Jahrestagung der ASCO 2024 präsentieren. Das Update der Studie wird sich auf den oralen CDK9-Inhibitor KB-0742 bei rezidivierten oder refraktären transkriptionell abhängigen fortgeschrittenen soliden Tumoren konzentrieren. Ziel der Studie ist es, die Sicherheit, Verträglichkeit und vorläufige Wirksamkeit von KB-0742 bei steigenden Dosisstufen zu bewerten. Die Präsentation wird von Brian A. Van Tine, M.D., Ph.D., von der Universität Washington in St. Louis, geleitet.
Positive
None.
Negative
None.
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (NCT04718675), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.
“We are looking forward to sharing updated data from KB-0742-1001, our ongoing Phase 1/2 trial of KB-0742, including data from the 80mg three days on/four days off dosing regimen. The trial is designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of KB-0742, an orally bioavailable and selective CDK9 inhibitor with a long half-life,” said Norbert Bischofberger, Ph.D., chief executive officer and president of Kronos Bio. “Our last update at the 2023 AACR-NCI-EORTC meeting showed that KB-0742 exhibited anti-tumor activity while maintaining an acceptable safety profile at the 60mg three-days-on, four-days-off dose, which is an important step as we seek to identify the optimal dose of KB-0742.”
Details for the ASCO 2024 abstract are as follows:
Title: Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors Presenter: Brian A. Van Tine, M.D., Ph.D., Washington University in St. Louis Abstract ID#: 3102 Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Location: Hall A, McCormick Place, Chicago, Illinois Poster Board #: 247 Date and Time: Saturday, June 1, 2024, from 9:00 a.m. to 12:00 p.m. CDT
About Kronos Bio, Inc. Kronos Bio is a biopharmaceutical company that is advancing an investigational CDK9 inhibitor compound, KB-0742, in a Phase 1/2 clinical trial as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors as well as a preclinical development candidate, KB-9558, targeting the KAT domain of p300 for multiple myeloma. The Company’s scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the Company on LinkedIn.
Company Contact: Margaux Bennett Vice President, Corporate Development and Investor Relations, Kronos Bio 650-781-5026 mbennett@kronosbio.com
FAQ
What is the focus of Kronos Bio's presentation at the 2024 ASCO Annual Meeting?
Kronos Bio will present a study update on the Phase 1/2 trial of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.
What is the goal of the ongoing Phase 1/2 trial KB-0742-1001?
The trial aims to assess the safety, tolerability, and preliminary efficacy of KB-0742 at increasing dose levels.
Who will be leading the presentation at ASCO 2024?
Brian A. Van Tine, M.D., Ph.D., from Washington University in St. Louis, will be leading the presentation on KB-0742 at the ASCO 2024 Annual Meeting.
kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
